Showing 1891-1900 of 2314 results for "".
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- Lumibird Medical Renames its Polish Subsidiary to Lumibird Medical Polskahttps://modernod.com/news/lumibird-medical-renames-its-polish-subsidiary-to-lumibird-medical-polska/2481613/Lumibird Medical Group has renamed its Polish subsidiary, Quantel Medical Polska, to Lumibird Medical Polska. After 5 years of existence, the Polish subsidiary, with a constant double-digit growth since its creation, has moved to a larger site in Warsaw. “
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Eyenovia Receives FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasishttps://modernod.com/news/eyenovia-receives-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis/2481603/Eyenovia announced that the FDA has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combinatio
- Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-completes-enrollment-ahead-of-schedule-in-its-phase-12a-trial-of-ea-2353-for-retinitis-pigmentosa/2481594/Endogena Therapeutics has announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stag
- Nanoscope Therapeutics Presents Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of RP at ARVOhttps://modernod.com/news/nanoscope-therapeutics-presents-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-rp-at-arvo/2481583/Nanoscope Therapeutics announced the presentation of key data from its phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARV
- Registration Now Open for Neuro-Optometric Rehabiliation Association 2023 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabiliation-association-2023-conference/2481568/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 33rd annual conference, October 5-8, at the Portland Marriot Downtown Waterfront in Portland, Oregon. The NORA annual conference is an event for eye care and other health care
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac
- American Academy of Optometry Foundation Now Accepting Applications for 2023 Residency Awardshttps://modernod.com/news/american-academy-of-optometry-foundation-now-accepting-applications-for-2023-residency-awards/2481516/The American Academy of Optometry Foundation is accepting requests for applications for its 2023 Residency Awards. Applications must be received by Tuesday, June 1, 2023. Award opportunities include: Douglas Hopkins Primary Care Eye Residency Award&nb